A new mouse model of ADHD for medication development

Petra Majdak, John R. Ossyra, Jessica M. Ossyra, Adam J. Cobert, Gabrielle C. Hofmann, Stephen Tse, Brent Panozzo, Elizabeth L. Grogan, Anastassia Sorokina, Justin S. Rhodes

Research output: Contribution to journalArticlepeer-review


ADHD is a major societal problem with increasing incidence and a stagnant track record for treatment advances. A lack of appropriate animal models has partly contributed to the incremental advance of this field. Hence, our goal was to generate a novel mouse model that could be useful for ADHD medication development. We reasoned that hyperactivity is a core feature of ADHD that could easily be bred into a population, but to what extent other hallmark features of ADHD would appear as correlated responses was unknown. Hence, starting from a heterogeneous population, we applied within-family selection over 16 generations to produce a High-Active line, while simultaneously maintaining an unselected line to serve as the Control. We discovered that the High-Active line demonstrated motor impulsivity in two different versions of the Go/No-go test, which was ameliorated with a low dose of amphetamine, and further displayed hypoactivation of the prefrontal cortex and dysregulated cerebellar vermal activation as indexed by c-Fos immunohistochemical staining. We conclude that the High-Active line represents a valid model for the Hyperactive-Impulsive subtype of ADHD and therefore may be used in future studies to advance our understanding of the etiology of ADHD and screen novel compounds for its treatment.

Original languageEnglish (US)
Article number39472
JournalScientific reports
StatePublished - Dec 20 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'A new mouse model of ADHD for medication development'. Together they form a unique fingerprint.

Cite this